CTOs on the Move

DyChrom

www.dychrom.com

 
DyChrom is a San Jose, CA-based company in the Business Services sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dychrom.com
  • 265 Meridian Ave Ste 8
    San Jose, CA USA 95126
  • Phone: 408.279.1611

Executives

Name Title Contact Details

Similar Companies

Creative Innovations

Creative Innovations is a Altoona, IA-based company in the Business Services sector.

Altimax Courier

Altimax Courier is a Dieppe, NB-based company in the Business Services sector.

Elite Group

Driven by passionate people and common goals, we are dedicated to the creation and development of cutting edge, innovative concepts and ideas for our customers while holding a deep respect for individuals inside and outside the company. We want our customers to enjoy and have fun with our products while giving them value and quality at the same time. We strive to foster a responsive, diverse organization that is highly motivated, team-oriented, and dedicated to innovative solutions and open communication. Our core values are at the heart of the positive reputation we continue to build wherever we operate. Elite Group services the following affiliated companies: Sensio Inc., L`Image Home Products Inc., Star Elite Inc. and DCore Lifestyle Inc. Each company is differentiated by their specific product line and are characterized by their innovative collections. Elite Group and its affiliated companies share in the same vision - creating a positive experience with any of our products, all which offer, innovation, quality and design.

Howard And Frost

Howard And Frost is a Seattle, WA-based company in the Business Services sector.

DRI Healthcare

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Over the course of three decades, we have been a trusted partner of royalty sellers and demonstrated strong execution, building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. That foundation sets us apart as we continue developing solutions for innovators while building and managing a risk-mitigated portfolio of therapeutic assets that generates attractive returns and growth potential for investors. We have deployed more than $2.5 billion, acquiring more than 70 royalties on 40-plus drugs.